{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:47:09Z","timestamp":1793886429610,"version":"4.8.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The cGAS-STING signaling pathway serves as a crucial bridge between innate and adaptive immunity, playing a dual role in breast cancer pathogenesis and treatment. This review delves into its complex functions within the breast tumor microenvironment, where pathway activation can either stimulate potent antitumor immunity or paradoxically promote tumor progression through immunosuppressive mechanisms. We examine the promising therapeutic strategy of utilizing STING agonists to transform immunologically quiescent tumors into T-cell-inflamed environments and their synergistic potential when combined with established modalities. The translation of these findings into clinical practice, however, faces considerable hurdles. This work critically summarizes the overarching challenges in the field and explores innovative approaches designed to overcome them. Finally, we present a forward-looking perspective on the rational development of next-generation immunotherapies centered on cGAS-STING pathway modulation, outlining key priorities for achieving its full therapeutic potential in breast cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1685931","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:53:38Z","timestamp":1767768818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The cGAS-STING signaling pathway: emerging targets and challenges in breast cancer immunotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Lei","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3456","article-title":"Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: A systematic review and meta-analysis","volume":"10","author":"Villacampa","year":"2024","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0301","article-title":"Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer","volume":"20","author":"Haiderali","year":"2024","journal-title":"Future Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-024-01649-z","article-title":"Current and future immunotherapy for breast cancer","volume":"17","author":"Heater","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-1427","article-title":"Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer","volume":"82","author":"Timperi","year":"2022","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-021-01223-x","article-title":"HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41421-024-00715-7","article-title":"Targeting SNRNP200-induced splicing dysregulation offers an immunotherapy opportunity for glycolytic triple-negative breast cancer","volume":"10","author":"Yang","year":"2024","journal-title":"Cell Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04847-2","article-title":"cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers","volume":"607","author":"Hong","year":"2022","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c11764","article-title":"Sensitizing tumors to immune checkpoint blockage via STING agonists delivered by tumor-penetrating neutrophil cytopharmaceuticals","author":"Hao","year":"2023","journal-title":"ACS Nano"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001372","article-title":"Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1-mediated immunoescape via STING-IFN signaling and extracellular vesicles","volume":"8","author":"Cheng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12943-024-02176-8","article-title":"PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies","volume":"23","author":"Jin","year":"2024","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-panTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2021.05.035","article-title":"Phase I\/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer","volume":"154","author":"Yuan","year":"2021","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: Results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"102500","DOI":"10.1016\/j.ctrv.2022.102500","article-title":"The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer","volume":"113","author":"von Arx","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13058-023-01724-2","article-title":"Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms","volume":"25","author":"Sigurjonsdottir","year":"2023","journal-title":"Breast Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00433-7","article-title":"Single-cell meta-analyses reveal responses of tumor-reactive CXCL13(+) T cells to immune-checkpoint blockade","volume":"3","author":"Liu","year":"2022","journal-title":"Nat Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s12672-025-02605-0","article-title":"The integrated single-cell analysis interpret the lactate metabolism-driven immune suppression in triple-negative breast cancer","volume":"16","author":"Gao","year":"2025","journal-title":"Discov Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","article-title":"Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer","volume":"185","author":"Nalio Ramos","year":"2022","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s42003-024-07341-9","article-title":"EZH2 elicits CD8(+) T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells","volume":"7","author":"Zhu","year":"2024","journal-title":"Commun Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-024-01957-5","article-title":"circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP\/IL-6 axis","volume":"23","author":"Zhao","year":"2024","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01007-z","article-title":"IL-17A-secreting gammadelta T cells promote resistance to CDK4\/CDK6 inhibitors in HR(+)HER2(-) breast cancer via CX3CR1(+) macrophages","volume":"6","author":"Petroni","year":"2025","journal-title":"Nat Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cllc.2021.05.007","article-title":"Comparison of SP142 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of atezolizumab in non-small cell lung cancer: results from the randomized OAK trial","volume":"23","author":"Gadgeel","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13855","article-title":"Clinicopathologic and genomic landscape of breast carcinoma brain metastases","volume":"26","author":"Huang","year":"2021","journal-title":"Oncologist"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.3390\/ijms25147517","article-title":"Immunotherapy in breast cancer","volume":"25","author":"Dvir","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.01.045","article-title":"Nanodrugs mediate TAMs-related arginine metabolism interference to boost photodynamic immunotherapy","volume":"367","author":"Chen","year":"2024","journal-title":"J Control Release"},{"key":"B46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12943-024-01995-z","article-title":"The incorporation of acetylated LAP-TGF-beta1 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis","volume":"23","author":"Yu","year":"2024","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3659714","DOI":"10.1155\/2022\/3659714","article-title":"MCT4\/lactate promotes PD-L1 glycosylation in triple-negative breast cancer cells","volume":"2022","author":"Duan","year":"2022","journal-title":"J Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1235902","article-title":"Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer","volume":"13","author":"Sammons","year":"2023","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-023-2499-2","article-title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K\/Akt\/mTOR pathway","volume":"67","author":"Ganesan","year":"2024","journal-title":"Sci China Life Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1186\/s12885-023-11551-5","article-title":"TIGIT(+) NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients","volume":"23","author":"Tsakmaklis","year":"2023","journal-title":"BMC Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i3.577","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events","volume":"16","author":"Jiang","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"11278","DOI":"10.1038\/s41598-024-61640-z","article-title":"Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification","volume":"14","author":"Lee","year":"2024","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"102964","DOI":"10.1016\/j.esmoop.2024.102964","article-title":"The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab","volume":"9","author":"Buisseret","year":"2024","journal-title":"ESMO Open"},{"key":"B55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/jpm12020323","article-title":"Homologous recombination deficiency (HRD) and BRCA 1\/2 gene mutation for predicting the effect of platinum-based neoadjuvant chemotherapy of early-stage triple-negative breast cancer (TNBC): A systematic review and meta-analysis","volume":"12","author":"Chai","year":"2022","journal-title":"J Pers Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.240575","article-title":"Use of pretreatment perfusion MRI-based intratumoral heterogeneity to predict pathologic response of triple-negative breast cancer to neoadjuvant chemoimmunotherapy","volume":"312","author":"Ramtohul","year":"2024","journal-title":"Radiology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGFbeta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3630","article-title":"Phase 1 and 2 clinical studies of the STING agonist ulevostinag with and without pembrolizumab in participants with advanced or metastatic solid tumors or lymphomas","volume":"31","author":"Harrington","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3911","article-title":"A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2024.12.02.626446","DOI":"10.1101\/2024.12.02.626446","article-title":"A TROP2\/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer","author":"Wu","year":"2024","journal-title":"bioRxiv"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"100467","DOI":"10.1016\/j.ctarc.2021.100467","article-title":"Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors","volume":"29","author":"Xiao","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2172","article-title":"Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial Malignancies","volume":"31","author":"Jaeger-Ruckstuhl","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00631-9","article-title":"Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms","volume":"19","author":"Cani","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2023.03.020","article-title":"Key determinants of success in fecal microbiota transplantation: From microbiome to clinic","volume":"31","author":"Porcari","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS-STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS-STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.apsb.2021.05.011","article-title":"The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy","volume":"12","author":"Oduro","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2023.04.006","article-title":"Structure-based mechanisms of 2\u20193\u2019-cGAMP intercellular transport in the cGAS-STING immune pathway","volume":"44","author":"Xie","year":"2023","journal-title":"Trends Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1095577","article-title":"From antiviral immunity to treat osteoporosis","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00018-024-05191-6","article-title":"cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors","volume":"81","author":"Li","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e13865","DOI":"10.1111\/acel.13865","article-title":"PTEN-induced kinase 1 is associated with renal aging, via the cGAS-STING pathway","volume":"22","author":"Ha","year":"2023","journal-title":"Aging Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"396","DOI":"10.20892\/j.issn.2095-3941.2024.0544","article-title":"Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p\/STING axis","volume":"22","author":"Yuan","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13578-023-01151-y","article-title":"MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer","volume":"13","author":"Bustos","year":"2023","journal-title":"Cell Biosci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.1038\/s41467-024-50999-2","article-title":"53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41419-020-2546-5","article-title":"Irradiation induces cancer lung metastasis through activation of the cGAS-STING-CCL5 pathway in mesenchymal stromal cells","volume":"11","author":"Zheng","year":"2020","journal-title":"Cell Death Dis"},{"key":"B80","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13045-021-01168-1","article-title":"Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway","volume":"14","author":"Ji","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165934","article-title":"POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS\/STING signaling","volume":"133","author":"Oh","year":"2023","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.str.2022.05.012","article-title":"Discovery of isonucleotidic CDNs as potent STING agonists with immunomodulatory potential","volume":"30","author":"Dejmek","year":"2022","journal-title":"Structure"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2022-0299","article-title":"Photodynamic immunotherapy using ADU-S100-modified nanoparticles to treat triple-negative breast cancer","volume":"18","author":"Ge","year":"2023","journal-title":"Nanomedicine (Lond)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202209910","article-title":"Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer","volume":"35","author":"Chen","year":"2023","journal-title":"Adv Mater"},{"key":"B86","doi-asserted-by":"publisher","first-page":"10.1038\/s41587-025-02556-5","DOI":"10.1038\/s41587-025-02556-5","article-title":"Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids","author":"Patel","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"283ra52","DOI":"10.1126\/scitranslmed.aaa4306","article-title":"STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade","volume":"7","author":"Fu","year":"2015","journal-title":"Sci Transl Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0246","article-title":"SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer","volume":"16","author":"Pascual","year":"2020","journal-title":"Future Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2201376119","article-title":"IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer","volume":"119","author":"Ong","year":"2022","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0932","article-title":"Tumor ENPP1 (CD203a)\/haptoglobin axis exploits myeloid-derived suppressor cells to promote post-radiotherapy local recurrence in breast cancer","volume":"12","author":"Ruiz-Fernandez de Cordoba","year":"2022","journal-title":"Cancer Discov"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09202-9","article-title":"Rescuing dendritic cell interstitial motility sustains antitumour immunity","author":"Tang","year":"2025","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.ccell.2022.11.005","article-title":"Interferon-dependent SLC14A1(+) cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer","volume":"40","author":"Ma","year":"2022","journal-title":"Cancer Cell"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","article-title":"STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"B94","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-019-0988-0","article-title":"MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer","volume":"18","author":"Weng","year":"2019","journal-title":"Mol Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403592","article-title":"Inactivated cGAS-STING signaling facilitates endocrine resistance by forming a positive feedback loop with AKT kinase in ER+HER2- breast cancer","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.94868","article-title":"A high immune-related index with the suppression of cGAS-STING pathway is a key determinant to herceptin resistance in HER2+ Breast cancer","volume":"20","author":"Cai","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.03.001","article-title":"Small molecules targeting the innate immune cGAS\u2013STING\u2013TBK1 signaling pathway","volume":"10","author":"Ding","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2235","article-title":"Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c02197","article-title":"Discovery of MK-1454: A potent cyclic dinucleotide stimulator of interferon genes agonist for the treatment of cancer","volume":"65","author":"Chang","year":"2022","journal-title":"J Med Chem"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-beta\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-3511","article-title":"Ionizable STING-activating nanoadjuvants enhance tumor immunogenicity and potentiate immunotherapy efficacy in solid tumors","volume":"84","author":"Xian","year":"2024","journal-title":"Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120638","article-title":"A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer","volume":"3","author":"Cheng","year":"2018","journal-title":"JCI Insight"},{"key":"B105","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.3390\/cancers14235962","article-title":"The microtubule destabilizer eribulin synergizes with STING agonists to promote antitumor efficacy in triple-negative breast cancer models","volume":"14","author":"Takahashi-Ruiz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308131","article-title":"Tumor Exosomal ENPP1 Hydrolyzes cGAMP to Inhibit cGAS-STING Signaling","volume":"11","author":"An","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202504252","article-title":"Nanosensitizer for cancer radioimmunotherapy via anti-IL-35 blockade boosted innate immunity activation","volume":"12","author":"Zheng","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1534928","article-title":"Development of a tertiary lymphoid structure-based prognostic model for breast cancer: integrating single-cell sequencing and machine learning to enhance patient outcomes","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1039\/D5QI00433K","article-title":"Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonists","volume":"12","author":"Dijkstra","year":"2025","journal-title":"Inorg Chem Front"},{"key":"B111","doi-asserted-by":"publisher","first-page":"0370","DOI":"10.34133\/research.0370","article-title":"Unlocking the therapeutic applicability of LNP-mRNA: chemistry, formulation, and clinical strategies","volume":"7","author":"Huang","year":"2024","journal-title":"Res (Wash D C)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-2531","article-title":"Harnessing STING signaling and natural killer cells overcomes PARP inhibitor resistance in homologous recombination-deficient breast cancer","volume":"85","author":"Pedretti","year":"2025","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1685931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:53:40Z","timestamp":1767768820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1685931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":112,"alternative-id":["10.3389\/fimmu.2025.1685931"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1685931","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1685931"}}